본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study

이용수 5

영문명
발행기관
대한신경정신의학회
저자명
JungYoon Heo Hawoo Yi Maurizio Fava David Mischoulon Kiwon Kim Sechang Yoon HongJin Jeon JeongEon Le
간행물 정보
『Psychiatry Investigation』제14권 제4호, 491~498쪽, 전체 8쪽
주제분류
의약학 > 정신과학
파일형태
PDF
발행일자
2017.07.31
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

Objective-Tamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression and anxiety and increase follicle-stimulating hormone (FSH) to patients. We compared anxiety and depression symptoms and FSH levels who received conventional tamoxifen alone and combination treatment of goserelin, a gonadotropin-releasing hormone (GnRH) analogue, with tamoxifen. Methods-Sixty-four premenopausal women with hormone receptor-positive early-stage breast cancer were included and were assigned randomly to receive either tamoxifen and goserelin combination or tamoxifen alone for 12 months. The participants were evaluated blindly using the Hamilton Depression and Anxiety Rating Scale, the Beck Depression Rating Scale, and the Albany Panic and Phobia Questionnaire (APPQ). Blood FSH levels were assessed at baseline, 6 and 12 months. Results-A significant time×group difference was detected in the agoraphobia trends subscale of the APPQ and in FSH levels. The combination group showed significantly less increases in agoraphobia subscale of APPQ and greater decreases in FSH level than those in the tamoxifen-alone group from baseline to 12 months of treatment. No significant differences for age, tumor grade, body mass index, or family history were found at baseline between the two groups. Conclusion-Our results suggest that the combination treatment of tamoxifen and goserelin resulted in less agoraphobia than tamoxifen alone in premenopausal women with breast cancer, which may associated with FSH suppression of goserelin.

목차

INTRODUCTION
METHODS
RESULTS
DISCUSSION
ACKNOWLEDGEMENTS
REFERENCES

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

JungYoon Heo,Hawoo Yi,Maurizio Fava,David Mischoulon,Kiwon Kim,Sechang Yoon,HongJin Jeon,JeongEon Le. (2017).Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. Psychiatry Investigation, 14 (4), 491-498

MLA

JungYoon Heo,Hawoo Yi,Maurizio Fava,David Mischoulon,Kiwon Kim,Sechang Yoon,HongJin Jeon,JeongEon Le. "Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study." Psychiatry Investigation, 14.4(2017): 491-498

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제